DYAI היקף יתרות המזומנים של החברה Dyadic

Dyadic International (DYAI) is currently utilizing internal reserves to develop its bioplatform. The issuer's revenues are based on the sale of C1 technology licenses for vaccine creation. Business efficiency relies on reducing protein production costs. The cash reserve trend on the GURU.Markets chart demonstrates liquidity, where the 0.01 indicator determines the status of the company's current cash parameter.
Dyadic International, Inc. (DYAI) - פילוחי מדדים ודוחות פיננסיים

The long-term sustainability of Dyadic International (DYAI) is determined by the volume of liquid assets that ensure autonomous business operations regardless of future liabilities. By analyzing the company's cash balance, an investor assesses the real margin of safety and the burn rate, which is critical for maintaining the costly C1 automated platform for robotic protein synthesis and the acceleration of laboratory research.